Scpharmaceuticals A Wholly Owned Sub Of Mannkind Patent-Cliff Exposure & CMS Drug Spending Portfolio

Scpharmaceuticals A Wholly Owned Sub Of Mannkind (US): 1 reconciled FDA prescription therapies, $30.1M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2040-01-01
2024 CMS Total Public Spend$30.1M
2024 Medicare Part D Spend$27.2M
2024 Medicaid Spend$2.9M
California HCAI SB 17 Filings1 WAC filings (max 19.3% 2-yr change)